Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNETICAL
2024-518708-29-00Phase 4Authorised
- Sponsor
- ULS Trás-os-Montes e Alto Douro
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tafamidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by ULS Trás-os-Montes e Alto Douro. Planned start Nov 2024; status: authorised.
02
Drugs
tafamidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2024-518708-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518708-29-00.